In Re Bristol-Myers Squibb Securities Litigation

361 F. Supp. 2d 229, 2005 WL 701134
CourtDistrict Court, S.D. New York
DecidedMarch 8, 2005
Docket02 CIV. 2251(LAP)
StatusPublished
Cited by17 cases

This text of 361 F. Supp. 2d 229 (In Re Bristol-Myers Squibb Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Bristol-Myers Squibb Securities Litigation, 361 F. Supp. 2d 229, 2005 WL 701134 (S.D.N.Y. 2005).

Opinion

AMENDED OPINION AND ORDER

PRESKA, District Judge.

Lead counsel for lead plaintiffs and the class (“Lead Counsel”) have petitioned for reimbursement of their expenses incurred *231 in this class action and an allowance of fees in connection with the settlement approved at a fairness hearing held on November 9, 2004 (the “Fairness Hearing”). The fees and expenses requested by counsel were set forth in the notice of said hearing, and no objection was made by any Class Member. 1

Lead Counsel have obtained for the Class a recovery of $300,000,000 (the “Settlement Fund”), of which Lead Counsel seek an award of 7.5%, net of approved notice costs and expenses, and reimbursement of litigation expenses in the amount of $557,580.75. At the Fairness Hearing, I reserved decision as to the fees and allowances to be made to Lead Counsel. For the reasons stated below, attorneys’ fees are awarded to Lead Counsel in the amount of 4% of the Settlement Fund, or $11,937,696.78.

BACKGROUND

The history of this case is set forth in detail in my April 1, 2004, Memorandum Opinion and Order. See In re Bristol-Myers Squibb Sec. Litig., 312 F.Supp.2d 549 (S.D.N.Y.2004). I restate only those facts that are pertinent to this motion. On September 19, 2001, Bristol-Myers Squibb (“BMS” or the “Company”) announced a $2 billion equity investment in ImClone pursuant to which the Company agreed to co-market and develop with ImClone the cancer treatment drug, Erbitux. Compl. ¶ 157. 2 However, on December 28, 2001, the Food and Drug Administration (“FDA”) informed ImClone, by way of a “refusal-to-file” (“RTF”) letter, that the FDA would not review the Erbitux Biolog-ies License Application because the data submitted by ImClone was insufficient to support fast track approval at that time. Compl. ¶¶ 181, 187-88. On March 21, 2002, this action commenced with the filing of a class action complaint asserting that various of the Company’s statements of optimism about the ImClone investment were false and misleading within the meaning of § 10(b) of the Securities and Exchange Act of 1934.

In April 2002, BMS issued its Form 10-K for the year ending December 31, 2001, in which it disclosed that certain of its domestic wholesalers had built up excess inventory of BMS’ pharmaceutical products. Compl. ¶¶ 113, 123. Also during April, the SEC began an informal inquiry into BMS’ wholesaler inventory buildup, which became a formal investigation in August 2002. Compl. ¶¶ 127, 130. On April 11, 2002, various plaintiffs filed a class action complaint alleging that the Company engaged in “a systematic program of moving sales from future periods [into the current period] in a process of what is sometimes called ‘channel stuffing.’ ” April 11 Compl. ¶ 35. 3 In late October 2002, the Company announced that, based on the recent advice of its accountant, PricewaterhouseCoopers LLP (“PwC”), the Company expected to restate its financial statements for certain prior periods. Compl. ¶ 134; Grayer Decl. Ex. A at 48. 4 In a stipulation signed on November 27, 2002, and filed on December 5, *232 2002, the parties agreed that an amended consolidated complaint would be served two weeks after the Company restated its earnings.

On March 10, 2003, BMS publicly announced the expected scope and substance of its restatement, which was formally contained in three amended public filings submitted to the SEC on March 19, 2003: a Form 10-K/A for the year ended December 31, 2001, and Forms 10-Q/A for the three-month periods ended March- 31, 2002, and June 30, 2002, (collectively, the “Restatement”). Compl. ¶ 2.

The parties entered into a stipulation and order on April 3, 2003, which modified the December 5 stipulation to give Lead Plaintiffs an opportunity to review the Company’s amended 2002 10-Q filings. Accordingly, on April 11, 2003, Teachers’ Retirement System of Louisiana, Louisiana State Employees’ Retirement System, General Retirement System of the City of Detroit, and Fresno County Employees’ Retirement Association (collectively, “Lead Plaintiffs”) filed the Complaint. Defendants moved to dismiss the Complaint beginning on August 1, 2003. Pursuant to the Private Securities Litigation Reform Act of 1995 (“PSLRA”), 15 U.S.C. § 78u-4, discovery was stayed during the pendency of Defendants’ motions to dismiss. Berger/Block Decl. ¶ 35. 5 On September 9, 2003, Lead Plaintiffs filed a single joint opposition to all pending motions to dismiss. Oral argument was held on March 29, 2004, and, on March 31, 2004, the motions to dismiss were granted, resulting in dismissal of the Complaint with prejudice.

Lead Plaintiffs filed a Notice of Appeal on April 28, 2004. While the appeal was pending, the parties engaged in settlement discussions which culminated in the Stipulation and Agreement of Settlement executed on July 29, 2004 (the “Stipulation”). Berger/Block Decl. ¶ 28. Just five days later, on August 4, 2004, th§ SEC announced the filing of a civil fraud action against BMS and the simultaneous settlement of that action. Berger/Block Decl. ¶ 31. Since that time, Lead Counsel and the SEC have worked cooperatively to distribute notices of settlement in both cases. Berger/Block Decl. ¶ 32.

Lead Counsel seek an award of attorneys’ in the amount of 7.5% of the $300,000,000 Settlement Fund, minus $1,000,000 in approved notice costs and $557,580,75 in expenses incurred by Plaintiffs’ Counsel, or $22,383,181.44. The fees sought result from two negotiations between Lead Plaintiffs and their counsel. The first negotiation occurred in preparation for the execution of retainer agreements with certain of the Lead Plaintiffs. Berger/Block Decl. ¶ 48; Lead PI. Decl. ¶ 14. 6 That agreement provided for a fee of 15% of the total recovery if such recovery was obtained upon either a decision on a motion to dismiss or prior to the commencement of discovery. Lead PL Decl. Ex. 1. Sometime after the Stipulation was entered, “Lead Plaintiffs and Lead Counsel revisited the retainer agreement in view of the fact that the Complaint had been dismissed with prejudice,” and they agreed to reduce the attorneys’ fees by half, to 7.5%. Lead Pl. Memo. at 23, 7 Lead *233 PI. Decl. ¶¶ 15-16, and Berger/Block Decl. ¶ 49. On October 19, 2004, Lead Counsel filed the present Motion for an Award of Attorneys’ Fees and Reimbursement of Expenses.

DISCUSSION

A. The Standard

Attorneys who create a common fund from which members of a class are compensated are entitled to “a reasonable fee — set by the court — to be taken from the fund.” Goldberger v. Integrated Resources, Inc., 209 F.3d 43, 47 (2d Cir.2000) (internal citation omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Story v. SEFCU
N.D. New York, 2021
Dial Corp. v. News Corp.
317 F.R.D. 426 (S.D. New York, 2016)
In Re Metlife Demutualization Litigation
689 F. Supp. 2d 297 (E.D. New York, 2010)
In re Currency Conversion Fee Antitrust Litigation
263 F.R.D. 110 (S.D. New York, 2009)
Carlson v. Xerox Corp.
596 F. Supp. 2d 400 (D. Connecticut, 2009)
In Re Telik, Inc. Securities Litigation
576 F. Supp. 2d 570 (S.D. New York, 2008)
In Re Cardinal Health Inc. Securities Litigations
528 F. Supp. 2d 752 (S.D. Ohio, 2007)
Brody v. Hellman
167 P.3d 192 (Colorado Court of Appeals, 2007)
In Re Excess Value Insurance Coverage Litigation
598 F. Supp. 2d 380 (S.D. New York, 2005)
In Re Elan Securities Litigation
385 F. Supp. 2d 363 (S.D. New York, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
361 F. Supp. 2d 229, 2005 WL 701134, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-bristol-myers-squibb-securities-litigation-nysd-2005.